DKSH has divested OLIC, a contract manufacturer of pharmaceutical products in Thailand, to Fuji Pharma Co. Ltd. DKSH plans to focus on its market expansion services in Asia. The transaction is subject to customary closing conditions.
Dr. Joerg Wolle, president and chief executive officer of DKSH Group, said, “This decision is in line with our strategy for sustainable profitable growth, where our focus is on our core competency as a provider of Market Expansion Services, from sourcing, marketing, sales, distribution to after-sales services. The OLIC contract manufacturing facility is a heritage, non-core activity of DKSH, and is more optimally positioned in the hands of Fuji, which has significant expertise in this sector. DKSH will be investing the proceeds into our core business to create higher value for shareholders.”
Mr. Hirofumi Imai, president and chief executive officer, Fuji Pharma said, “This acquisition is an important step for Fuji Pharma in our expansion plans outside of Japan. Through the acquisition of OLIC, we are gaining a best-in-class contract manufacturing business that is highly reputable, profitable, and well run by highly trained and competent staff according to international GMP standards. OLIC fits perfectly with our existing operations and business in Japan and in Asia, and we are committed to investing and growing OLIC even more, and further enhancing its already well-established reputation and performance.”